A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. - Wikidata - wikimedia - TriplyDB

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

http://www.wikidata.org/entity/Q33591830

about

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.

P2860

Q37725415-5C5420DA-E12F-4DDC-88E7-C7F0CE29694E

P2860

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

http://www.wikidata.org/entity/Q33591830

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

A phase I-II trial of fludarab ...... sly treated patients with CLL.

@ast

A phase I-II trial of fludarab ...... sly treated patients with CLL.

@en

type

label

A phase I-II trial of fludarab ...... sly treated patients with CLL.

@ast

A phase I-II trial of fludarab ...... sly treated patients with CLL.

@en

prefLabel

A phase I-II trial of fludarab ...... sly treated patients with CLL.

@ast

A phase I-II trial of fludarab ...... sly treated patients with CLL.

@en

P1433

Q33591830-2B75A543-ADB1-48FD-9152-2AACC7D4D296

P1476

Q33591830-74D13141-0800-4D6E-9A8E-500C69105BAF

P2093

Q33591830-0261634B-7AE9-4A88-AABF-56A895602BCD

Q33591830-2BA3717B-50B3-4A3A-88E1-A91916D97830

Q33591830-369D597D-A0A6-4EAC-9E05-6A9E3E2BA153

Q33591830-3DECE28C-F774-4F5E-BA62-10F21E6CE340

Q33591830-45B78313-38DC-4353-91FA-708FE6878E7E

Q33591830-6C5B2ADD-DD99-40EE-858B-073E40625C76

Q33591830-C4553EAE-4598-4B0C-8BB5-30EC12233D81

Q33591830-D43D4288-0E78-4AF3-9B25-4F87536D6408

P2860

Q33591830-09247937-D646-45F1-AE40-F9F33894F6E5

Q33591830-199C445E-E67D-4ABE-B194-478E15743C55

Q33591830-1CBEC95E-D6DC-4521-8A47-FE2323ABD767

Q33591830-2AAD392A-9F0D-46C2-AC40-B701BFCD7686

Q33591830-2D56DB1F-304B-4011-9BE8-D7164ECD2ADA

Q33591830-36BFE88E-EC84-41E7-8725-0C421AD18FAC

Q33591830-46750ADF-F403-43F9-B898-69DEE2C055F9

Q33591830-4859EAA1-DDF5-441B-BD14-0E3F25C80A43

Q33591830-50187E69-5078-4C5E-99A4-04D0C204AF63

Q33591830-5A07D42F-DF7A-4631-B089-DF1F1C85239F

P304

Q33591830-362B267E-5ADF-4A41-A760-F2721B61F441

P31

Q33591830-70C43FDD-C79C-4C61-ADDC-EC9E604CAB8D

P356

Q33591830-AF287A63-73B7-4670-AC79-5E977543248C

P407

Q33591830-32C9F52C-E253-4EA3-A18E-6047E929E404

P433

Q33591830-0594D14B-8BA9-47AF-9C9E-DDEBB7A6E3A0

P478

Q33591830-4876CD6C-CDFC-405F-9763-DC38C3CB4BB4

P50

Q33591830-21EFA1DE-65B8-47D1-A51C-5C12545E1D4D

Q33591830-347DFB4D-C214-4270-821A-9E6FFBDA07A1

Q33591830-54DB2A0B-FFAC-4B3E-865E-00FC8479477C

Q33591830-7CF398E5-F38F-4BFF-8977-18CB3DE374D8

P577

Q33591830-B89C2D2A-E802-4D1C-A41D-9C8F6F78ACED

P698

Q33591830-0E835ACC-62B9-4667-9C2D-F5913FBE0B72

P921

Q33591830-2BD41543-6B48-4BFB-AC16-9C77430BF4B4

Q33591830-8B4F6815-29DC-4191-9882-03E0BE97689C

P932

Q33591830-BCB6BFA5-FCDF-489D-845B-653634E74B5B

P356

ONCOTARGET.12054

P1433

P1476

A phase I-II trial of fludarab ...... sly treated patients with CLL.

@en

P2093

Francesco Paolo Tambaro

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Kumudha Balakrishnan

http://www.w3.org/2001/XMLSchema#string

Mary L Ayres

http://www.w3.org/2001/XMLSchema#string

Nitin Jain

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

Tapan M Kadia

http://www.w3.org/2001/XMLSchema#string

Varsha Gandhi

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relap

P304

22104-22112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12054

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2016-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27655665

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

5400650

http://www.w3.org/2001/XMLSchema#string